A Study to Compare the Efficacy of Rivaroxaban, Warfarin and LMWH for the Treatment of VTE in Newly Diagnosed Cancer Patients

Trial Profile

A Study to Compare the Efficacy of Rivaroxaban, Warfarin and LMWH for the Treatment of VTE in Newly Diagnosed Cancer Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Low molecular weight heparin; Warfarin
  • Indications Venous thromboembolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results comparing the risk of major bleeding presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 14 Jul 2016 New trial record
    • 07 Jun 2016 Results assessing association between the duration of anticoagulation and VTE recurrence (n=1158) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top